In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria

  • J. Wüst
  • U. Hardegger


The in vitro activity of ceftriaxone combined with tazobactam against 190 strains of anaerobic bacteria was compared with that of amoxicillin with clavulanic acid, ampicillin with sulbactam, piperacillin alone and with tazobactam, cefoxitin, and imipenem, i.e. beta-lactam antibiotics established in the treatment of anaerobic infections. All anaerobes tested were susceptible to ≤32 mg/l ceftriaxone when tazobactam was added at fixed ratios (ceftriaxone to tazobactam) of 2:1 and 8:1 and at constant concentrations of 2,4 and 8 mg/l, respectively. When 4 mg/l tazobactam was added, the MICs of ceftriaxone for 83 of 94 strains of theBacteroides fragilis group were reduced by a factor of 8 to 512; for eight strains, this reduction was two to fourfold. Only the MICs of ceftriaxone for threeBacteroides fragilis strains were not influenced.


Internal Medicine Ampicillin Amoxicillin Ceftriaxone Imipenem 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Murray PR, Jones RN, Allen SD, Erwin ME, Fuchs PC, Gerlach EH Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria. Diagnostic Microbiology and Infectious Disease 1993, 16: 191–203.CrossRefPubMedGoogle Scholar
  2. 2.
    Rolfe RD, Finegold SM Comparative in vitro activity of ceftriaxone against anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1982, 22: 338–341.PubMedGoogle Scholar
  3. 3.
    Wexler HM Susceptibility testing of anaerobic bacteria: myth, magic, or method. Clinical Microbiology Reviews 1991, 4: 470–484.PubMedGoogle Scholar
  4. 4.
    Appelbaum PC, Philippon A, Jacobs MR, Spangler SK, Gutmann L Characterization of β-lactamases from non-Bacteroides fragilis groupBacteroides spp. belonging to seven species and their role in β-lactam resistance. Antimicrobial Agents and Chemotherapy 1990, 34: 2169–2176.PubMedGoogle Scholar
  5. 5.
    Finegold SM Mechanisms of resistance in anaerobes and new developments in testing. Diagnostic Microbiology and Infectious Disease 1989, 12, Supplement: 117–120.CrossRefGoogle Scholar
  6. 6.
    Nord CE, Hedberg M Resistance to β-lactam antibiotics in anaerobic bacteria. Reviews of Infectious Diseases 1990: 12, Supplement 2: 231–234.Google Scholar
  7. 7.
    Wexler HM, Molitoris E, Finegold SM Effect of β-lactamase inhibitors on the activities of various β-lactam agents against anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1991, 35: 1219–1224.PubMedGoogle Scholar
  8. 8.
    Appelbaum PC Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria. Journal of Antimicrobial Chemotherapy 1993, 31, Supplement A: 29–38.Google Scholar
  9. 9.
    National Committee for Clinical Laboratory Standards Methods for antimicrobial susceptibility testing of anaerobic bacteria, Approved standard M11-A2. NCCLS, Villanova, PA, 1990.Google Scholar
  10. 10.
    Sanford JP Guide to antimicrobial therapy 1993. Antimicrobial Therapy, Inc., Dallas, TX, 1993.Google Scholar
  11. 11.
    Maskell JP, Nasu M, Williams JD Cephalosporin resistance on theBacteroides fragilis group and the effect of clavulanic acid. Journal of Antimicrobial Chemotherapy 1984, 13: 23–30.Google Scholar
  12. 12.
    Holdeman LV, Cato EP, Moore WEC (ed Anaerobe laboratory manual, 4th edition. Virginia Polytechnic Institute and State University, Blacksburg, VA, 1977.Google Scholar
  13. 13.
    O'Callaghan CH, Morris A, Kirby SM, Shingler AH Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrobial Agents and Chemotherapy 1972, 1: 283–288.PubMedGoogle Scholar
  14. 14.
    National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing. Fourth informational supplement. NCCLS document M100-S4. NCCLS, Villanova, PA, 1992.Google Scholar
  15. 15.
    Wüst J, Wilkins TD Effect of clavulanic acid on anaerobes resistant to beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy 1978, 13: 130–133.Google Scholar
  16. 16.
    Hedberg M, Lindqvist L, Tunér K, Nord CE Effect of clavulanic acid, sulbactam and tazobactam on three different β-lactamases fromBacteroides uniformis, Clostridium butyricum andFusobacterium nucleatum. Journal of Antimicrobial Chemotherapy 1992, 30: 17–25.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1994

Authors and Affiliations

  • J. Wüst
    • 1
  • U. Hardegger
    • 1
  1. 1.Department of Medical MicrobiologyUniversity of ZurichZürichSwitzerland

Personalised recommendations